Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

Chemical Compound Review:

AGN-PC-00KL3G 7,7-dimethyl-6-oxo-1,2,5- dithiazepane-4...

Synonyms: CCRIS 5263, SA-981, AC1L1HRC, LS-63182, SA 981, ...

Distler, J.H. et al., Wielandt, A.M. et al., Hashimoto, K. et al.

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

High impact information on SA 981

In contrast, SA 981 did not influence the stability of VEGF mRNA as analyzed with actinomycin D assays [1].
Specific binding of NF-kappaB protein to its binding site after treatment with SA 981 was confirmed by electrophoretic mobility shift assay [1].
SA 96, and particularly its metabolite SA 981, increased the levels of vascular endothelial growth factor (VEGF) mRNA and protein dose-dependently in dermal fibroblasts from patients with SSc and healthy control subjects without influencing cell viability [1].
Moreover, both bucillamine and SA 981 significantly increased the expressions of Mrp2/MRP2 and GCLC proteins in both cell lines [2].
Finally, in both cell lines, bucillamine and SA 981 increased the GSH content two- to three-fold [2].

Anatomical context of SA 981

Bucillamine, and its metabolites SA 679, and SA 981 inhibited mitogen induced T cell responses [3].

References

Bucillamine induces the synthesis of vascular endothelial growth factor dose-dependently in systemic sclerosis fibroblasts via nuclear factor-kappaB and simian virus 40 promoter factor 1 pathways. Distler, J.H., Hagen, C., Hirth, A., Müller-Ladner, U., Lorenz, H.M., del Rosso, A., Michel, B.A., Gay, R.E., Nanagara, R., Nishioka, K., Matucci-Cerinic, M., Kalden, J.R., Gay, S., Distler, O. Mol. Pharmacol. (2004) [Pubmed]
Bucillamine induces glutathione biosynthesis via activation of the transcription factor Nrf2. Wielandt, A.M., Vollrath, V., Farias, M., Chianale, J. Biochem. Pharmacol. (2006) [Pubmed]
Immunosuppression by the disease modifying antirheumatic drug bucillamine: inhibition of human T lymphocyte function by bucillamine and its metabolites. Hashimoto, K., Lipsky, P.E. J. Rheumatol. (1993) [Pubmed]

Contributions to this collaborative article are from individual authors of WikiGenes or mined by the WikiGenes Data Mining Engine from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use apsburg

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

Editor

Share